Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines

Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines

Bruton’s tyrosine kinase (BTK) is a key regulator of the B-cell receptor signaling pathway, and aberrant B-cell receptor (BCR) signaling has been implicated in the survival of malignant B-cells. However, responses of the diffuse large B-cell lymphoma (DLBCL) to inhibitors of BTK (BTKi) are infrequen...

Full description

Bibliographic Details
Main Authors: Ryohei Kozaki, Meike Vogler, Harriet S. Walter, Sandrine Jayne, David Dinsdale, Reiner Siebert, Martin J.S. Dyer, Toshio Yoshizawa
Format: Article
Language:English
Published: MDPI AG 2018-04-01
Series:Cancers
Subjects:
DLBCL
BCR signaling
BTK
combination therapy
Online Access:http://www.mdpi.com/2072-6694/10/4/127

Internet

http://www.mdpi.com/2072-6694/10/4/127

Similar Items